Cancer Immunotherapy Specialists are medical professionals who focus on utilizing the body's immune system to fight cancer. Unlike conventional treatments such as chemotherapy and radiation, immunotherapy works by stimulating or enhancing the immune system’s natural ability to detect and destroy cancer cells. These specialists are trained in administering advanced immunotherapy treatments, including immune checkpoint inhibitors, CAR T-cell therapy, cancer vaccines, and monoclonal antibodies. By harnessing the power of the immune system, they offer patients a more targeted and often less toxic treatment option compared to traditional therapies.
These specialists work closely with oncologists to design individualized treatment plans based on the specific cancer type, its genetic makeup, and the patient’s overall health. Cancer immunotherapy specialists are skilled at monitoring the patient’s progress and managing any potential side effects, which can include immune-related reactions such as inflammation or fatigue. Their expertise is particularly crucial in treating cancers that have proven difficult to treat with traditional methods, such as melanoma, lung cancer, and certain types of blood cancers. Cancer immunotherapy specialists are often involved in groundbreaking clinical research. They contribute to the development of new therapies and explore innovative combinations of immunotherapies to increase effectiveness. As this field continues to grow, cancer immunotherapy specialists play a vital role in transforming cancer treatment and providing new hope for patients who may not have had many options in the past.
Title : A novel blood-based mRNA genomics technology for cancer diagnosis and treatment
Rajvir Dahiya, University of California San Francisco, United States
Title : tRNA-derived fragment 3′tRF-AlaAGC modulates cell chemoresistance and M2 macrophage polarization via binding to TRADD in breast cancer
Feng Yan, The Affiliated Cancer Hospital of Nanjing Medical University, China
Title : Integrating single-cell and spatial transcriptomics to uncover and elucidate GP73-mediated pro-angiogenic regulatory networks in hepatocellular carcinoma
Jiazhou Ye, Guangxi Medical University Cancer Hospital, China
Title : Unveiling the synergism of radiofrequency therapy and graphene nanocomposite in tumor cell viability assay
Paulo Cesar De Morais, Catholic University of Brasilia, Brazil
Title : Analysis of the dynamic evolution and influencing factors of nutritional risk in breast cancer patients during treatment
Jingwen Yan, Sun Yat-sen University, China
Title : Integrative multi-omics reveals metabolic–stemness coupling and novel therapeutic targets in osteosarcoma chemoresistance
Jinyan Feng, Tianjin Medical University Cancer Institute and Hospital, China